Symbollon Pharmaceuticals Inc. (SYMBA)
Interview with:
Paul Desjourdy, President, CFO and COO
Business News, Financial News, Stocks, Money & Investment Ideas, CEO Interview
and Information on their
development and commercialization of proprietary drugs based on its molecular iodine technology with their IoGen™  already in clinical trials as a potential treatment for moderate to severe cyclic pain and tenderness (clinical mastalgia) associated with fibrocystic breast disease (FBD.

wpe4D.jpg (6486 bytes)

Cover Story

CEOCFO Interview Index

CEOCFO Current Issue

Cover Story Archives

Future Features

Analyst Interviews

Corporate Financials

Archived Interviews
 

About CEOCFOinterviews.com

Contact & Ordering

This is a printer friendly page!

With no safe and effective products on the market for treating fibrocystic breast disease Symbollon Pharmaceuticals is taking the lead as it enters the final stages of testing for its IoGen™ drug

wpe5B.jpg (2967 bytes)

Healthcare
Biotech and Drugs
(SYMBA-OTC)

Symbollon Pharmaceuticals Inc.


wpe61.jpg (4959 bytes)

Paul Desjourdy
President, CFO and COO

Interview conducted by:
Lynn Fosse
Senior Editor

CEOCFOinterviews.com
June 2004

Instant Access:
To view a copy of this highly informative interview, left click here: View
SYMBA

disclaimer

Newsflash!

To view Releases highlight & left click on the company name!

 

ceocfointerviews.com does not purchase or make
recommendation on stocks based on the interviews published.

.